• Skip to main content

DistilINFO LifeSciences

Weekly round up from Life Sciences Industry.

  • Publications
    • Home
    • DistilINFO HealthPlan
    • DistilINFO HospitalIT
    • DistilINFO IT
    • DistilINFO Retail
    • DistilINFO POPHealth
    • DistilINFO Ageing
    • DistilINFO Life Sciences
    • DistilINFO GovHealth
    • DistilINFO EHS
    • DistilINFO HealthIndia
    • Subscribe
    • Submit Article
    • Advertise
    • Newsletters

KT Corp. Partners with Catholic Medical Center to Develop New DTx

Share:

January 18, 2022

KT Corporation, one of South Korea’s biggest telecommunications firms, has signed a memorandum of understanding with the Catholic Medical Center of the Catholic University of Korea to jointly develop digital treatment devices.

WHAT IT’S ABOUT

Under the agreement, the companies will jointly cooperate to develop a platform to create digital therapeutics (DTx) devices and build prototypes. They will also hold an idea contest for digital treatment devices.

On its end, KT Corp. said it plans to combine AI, big data, and cloud technologies with DTx. Aside from that, it will support local and international marketing efforts around digital treatment devices. On the other hand, the CMC will provide the research personnel and clinical infrastructure and will also support the medical and academic exchanges.

MARKET SNAPSHOT

In June, KT Corp. also entered into an agreement with US-based NeuroSigma to develop and market electronic therapies for neurological and neuropsychological disorders, like ADHD, depression, and epilepsy. The latter created the first US FDA-approved non-drug therapy device for treating pediatric ADHD, Monarch eTNS, which uses non-invasive external trigeminal nerve stimulation.

Want to publish your own articles on DistilINFO Publications?

Send us an email, we will get in touch with you.

In the DTx realm, Japanese companies are leading the pack in the Asia-Pacific. Sumitomo Dainippon Pharma Co. and BehaVR, an American mental health firm, have signed deals to create and sell prescription DTx for major mental health disorders. Under these agreements, Sumitomo will fund the development of three new virtual reality-based therapies for social anxiety disorder, generalized anxiety disorder, and major depressive disorder (MDD). Together, they will seek US FDA approvals for the pipeline devices.

In early 2021, Otsuka Pharmaceutical and Click Therapeutics in the US conducted a fully remote clinical trial to measure a DTx intervention’s effectiveness in reducing symptoms of depression among adults with MDD.

According to Grand View Research, the global digital therapeutics market is expected to hit $19.1 billion in value by 2028, growing at a 23.1% CAGR from last year.

ON THE RECORD

“In cooperation with the CMC, we will create various references in the field of digital treatment devices, such as addiction improvement, rehabilitation, and chronic disease management”, said Jae-Ho Song, VP for AI/DX convergence business division at KT Corp.

“The digital treatment device market is expected to expand further and data-based customized treatment is expected,” Kim Dae-jin, president of the Information Convergence Promotion Centre at CMC, also commented.

Source: Mobihealthnews

Coffee with DistilINFO's Morning Updates...

Sign up for DistilINFO e-Newsletters.

Just a little bit more about you...
PROCEED
Choose Lists
BACK

Related Stories

  • European Ecosystem for Health Tech Launched By Sanofi, Capgemini, Generali and OrangeEuropean Ecosystem for Health Tech Launched By Sanofi, Capgemini, Generali and Orange
  • Indegene Acquires DT Associates, Provides End-To-End Enterprise Solution For Customer Excellence – From Consulting To OperationsIndegene Acquires DT Associates, Provides End-To-End Enterprise Solution For Customer Excellence – From Consulting To Operations
  • Conduit Pharmaceuticals and Murphy Canyon Acquisition Corp. Announce Completion of Business CombinationConduit Pharmaceuticals and Murphy Canyon Acquisition Corp. Announce Completion of Business Combination
  • Entheon Biomedical Corp. Announces Acquisition of HaluGen Life Sciences Inc.Entheon Biomedical Corp. Announces Acquisition of HaluGen Life Sciences Inc.
  • Avanti Polar Lipids Agrees to be Acquired by CrodaAvanti Polar Lipids Agrees to be Acquired by Croda
  • Nebraska Medicine Awards 10-Year Contract Extension to Sodexo, a Strategic Partner in Enhancing the Patient ExperienceNebraska Medicine Awards 10-Year Contract Extension to Sodexo, a Strategic Partner in Enhancing the Patient Experience
  • Wolters Kluwer Launches Global COVID-19 Search Intensity Monitoring MapWolters Kluwer Launches Global COVID-19 Search Intensity Monitoring Map
  • FDA Clears ICU Device That Predicts Respiratory Failure to Support COVID-19FDA Clears ICU Device That Predicts Respiratory Failure to Support COVID-19

Trending This Week

Sorry. No data so far.

About Us

DistilINFO is media company that publishes Industry news, views and Interviews. We distil the information for you – saving time and keeping you up to date on your interest areas.

More About Us

Follow Us


Useful Links

  • Subscribe
  • Contact
  • Advertise
  • Privacy Policy
  • Terms of Service
  • Feedback

All Publications

  • DistilINFO HealthPlan Advisory
  • DistilINFO HospitalIT Advisory
  • DistilINFO IT Advisory
  • DistilINFO Retail Advisory
  • DistilINFO POPHealth Advisory
  • DistilINFO Ageing Advisory
  • DistilINFO Life Sciences Advisory
  • DistilINFO GovHealth Advisory
  • DistilINFO EHS Advisory
  • DistilINFO HealthIndia Advisory

© DistilINFO Publications